Altamira Therapeutics Ltd. (NASDAQ: CYTO) stock fell -5.36% on Friday to $0.26 against a previous-day closing price of $0.28. With 0.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.41 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2800 whereas the lowest price it dropped to was $0.2402. The 52-week range on CYTO shows that it touched its highest point at $13.52 and its lowest point at $0.23 during that stretch. Beta for the stock currently stands at 1.24.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CYTO was down-trending over the past week, with a drop of -20.66%, but this was down by -27.00% over a month. Three-month performance dropped to -68.07% while six-month performance fell -81.60%. The stock lost -96.58% in the past year, while it has lost -94.54% so far this year.
Float and Shares Shorts:
At present, 8.83 million CYTO shares are outstanding with a float of 8.78 million shares on hand for trading. On Aug 30, 2023, short shares totaled 48010.0, which was 0.60% higher than short shares on Jul 30, 2023. In addition to Dr. Thomas Meyer Ph.D. as the firm’s Founder, Chairman, CEO & MD, Mr. Marcel Gremaud CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.07% of CYTO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.82% of CYTO, in contrast to 0.01% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CYTO with 0.83% of the stake, Citadel Securities LLC holds 72,931 shares worth 72,931. A second-largest stockholder of CYTO, Morgan Stanley Smith Barney LLC, holds 500 shares, controlling over 0.01% of the firm’s shares. Group One Trading LP is the third largest shareholder in CYTO, holding 298 shares or 0.00% stake. With a 0.01% stake in CYTO, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 943 shares are owned by the mutual fund manager. The Blackstone Alternative Multi Stra, which owns about 0.00% of CYTO stock, is the second-largest Mutual Fund holder. It holds 0 shares valued at 0.0.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CYTO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CYTO analysts setting a high price target of $286.10 and a low target of $286.10, the average target price over the next 12 months is $286.10. Based on these targets, CYTO could surge 109938.46% to reach the target high and rise by 109938.46% to reach the target low. Reaching the average price target will result in a growth of 109938.46% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
